

Anti-VEGFR2 (Ramucirumab), Human IgG1 Antibody

06/20

CATALOG NO.: A2139-100 (100 µg)

BACKGROUND DESCRIPTION: Ramucirumab is a fully human IgG1 monoclonal antibody that binds to the vascular endothelial growth factor receptor 2 (VEGFR2) and inhibits association with its ligands (VEGF A, C, and D). This prevents VEGF-mediated proliferation, migration of endothelial cells, and angiogenesis. Ramucirumab was developed by ImClone Systems and received FDA approval in 2014 for the treatment of advanced gastric cancer/gastro-esophageal junction (GEJ) adenocarcinoma. Recently, Ramucirumab has also been approved for use in combination treatment of metastatic non-small lung carcinoma (NSLC), metastatic colorectal cancer (mCRC), and hepatocellular carcinoma (HCC). Ramucirumab is currently marketed under the trade name CYRAMZA®.

ALTERNATE NAMES: 1121B, IMC-1121B, LY3009806, CD309, KDR, Cyramza

ANTIBODY TYPE: Monoclonal

CONCENTRATION: 1 mg/ml

HOST/ISOTYPE: Human / IgG1, kappa

SOURCE: CHO cells

IMMUNOGEN: Ramucirumab

MOLECULAR WEIGHT: 143.6 kDa

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C

APPLICATIONS AND USAGE: In vitro studies

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-IL-2R alpha (Daclizumab), Human IgG1 Antibody (A1099)
 Anti-PD-1 (Nivolumab), Humanized Antibody (A1307)
 Anti-VEGF (Bevacizumab), humanized Antibody (A1045)
 Anti-TNF-α (Adalimumab), humanized Antibody (A1048)
 Anti-IL-2R alpha (CD25) (Basiliximab), Human IgG1 Antibody (A1098)

FOR RESEARCH USE ONLY! Not to be used on humans.